# Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

> **NCT03322137** · PHASE2 · COMPLETED · sponsor: **Sienna Biopharmaceuticals** · enrollment: 208 (actual)

## Conditions studied

- Pruritus
- Psoriasis Vulgaris

## Interventions

- **DRUG:** SNA-120
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03322137
- **Lead sponsor:** Sienna Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-10-22
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322137, "Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03322137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*